{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:51:48Z","timestamp":1776855108667,"version":"3.51.2"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.phrs.2016.09.011","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T12:18:39Z","timestamp":1474028319000},"page":"395-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"special_numbering":"PA","title":["Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9861-4139","authenticated-orcid":false,"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2016.09.011_bib0005","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/361226a0","article-title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2016.09.011_bib0010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","article-title":"Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia","volume":"72","author":"Tsukada","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2016.09.011_bib0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1126\/science.8332900","article-title":"Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes","volume":"261","author":"Thomas","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.09.011_bib0020","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1126\/science.8332901","article-title":"Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice","volume":"261","author":"Rawlings","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.09.011_bib0025","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0022-3476(62)80092-4","article-title":"A decade with agammaglobulinemia","volume":"60","author":"Bruton","year":"1962","journal-title":"J. Pediatr."},{"key":"10.1016\/j.phrs.2016.09.011_bib0030","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3324\/haematol.2014.119123","article-title":"The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia","volume":"100","author":"Wiestner","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.phrs.2016.09.011_bib0035","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"M\u00f3csai","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phrs.2016.09.011_bib0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton's tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2016.09.011_bib0045","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbrc.2010.07.092","article-title":"RAF protein-serine\/threonine kinases: structure and regulation","volume":"399","author":"Roskoski","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2016.09.011_bib0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bbrc.2011.11.145","article-title":"MEK1\/2 dual-specificity protein kinases: structure and regulation","volume":"417","author":"Roskoski","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2016.09.011_bib0055","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.09.011_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.09.011_bib0065","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1084\/jem.20011866","article-title":"The B cell antigen receptor controls integrin activity through Btk and PLC\u03b32","volume":"198","author":"Spaargaren","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.phrs.2016.09.011_bib0070","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.09.011_bib0075","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbrc.2004.09.171","article-title":"Src protein-tyrosine kinase structure and regulation","volume":"324","author":"Roskoski","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2016.09.011_bib0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.09.011_bib0085","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jbior.2013.08.001","article-title":"Phospholipase C-\u03b2 in immune cells","volume":"53","author":"Kawakami","year":"2013","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.phrs.2016.09.011_bib0090","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","article-title":"Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification","volume":"9","author":"Hanks","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2016.09.011_bib0095","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.09.011_bib0100","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1126\/science.1862343","article-title":"Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.09.011_bib0105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.tibs.2010.09.006","article-title":"Protein kinases: evolution of dynamic regulatory proteins","volume":"36","author":"Taylor","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.phrs.2016.09.011_bib0110","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1098\/rstb.2012.0054","article-title":"Evolution of the eukaryotic protein kinases as dynamic molecular switches","volume":"367","author":"Taylor","year":"2012","journal-title":"Philos. Trans. R Soc. Lond. B: Biol. Sci."},{"key":"10.1016\/j.phrs.2016.09.011_bib0115","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.molcel.2004.08.024","article-title":"Regulation of protein kinases; controlling activity through activation segment conformation","volume":"15","author":"Nolen","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2016.09.011_bib0120","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1126\/science.271.5250.822","article-title":"Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases","volume":"271","author":"Rawlings","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.09.011_bib0125","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.09.011_bib0130","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.09.011_bib0135","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.09.011_bib0140","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.09.011_bib0145","doi-asserted-by":"crossref","first-page":"e1001680","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2016.09.011_bib0150","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.09.011_bib0155","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm400378w","article-title":"KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space","volume":"57","author":"van Linden","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2016.09.011_bib0160","first-page":"4","article-title":"Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate","author":"Wang","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.phrs.2016.09.011_bib0165","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.09.011_bib0170","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.8961","article-title":"Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents","author":"Inamdar","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2016.09.011_bib0175","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.09.011_bib0180","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","article-title":"FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia","volume":"21","author":"de Claro","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2016.09.011_bib0185","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrc.2016.8","article-title":"The molecular pathogenesis of chronic lymphocytic leukaemia","volume":"16","author":"Fabbri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2016.09.011_bib0190","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.09.011_bib0195","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2146\/ajhp140760","article-title":"Ibrutinib for treatment of chronic lymphocytic leukemia","volume":"73","author":"Vela","year":"2016","journal-title":"Am. J. Health. Syst. Pharm."},{"key":"10.1016\/j.phrs.2016.09.011_bib0200","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.09.011_bib0205","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.09.011_bib0210","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.09.011_bib0215","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.phrs.2016.09.011_bib0220","doi-asserted-by":"crossref","DOI":"10.1021\/acschembio.6b00480","article-title":"Battling Btk mutants with noncovalent inhibitors that overcome cys481 and thr474 mutations","author":"Johnson","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2016.09.011_bib0225","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nsmb.1486","article-title":"Activation of tyrosine kinases by mutation of the gatekeeper threonine","volume":"15","author":"Azam","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.phrs.2016.09.011_bib0230","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/leu.2014.263","article-title":"Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors","volume":"29","author":"Cheng","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2016.09.011_bib0235","doi-asserted-by":"crossref","first-page":"13283","DOI":"10.1073\/pnas.0702654104","article-title":"The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib","volume":"104","author":"Hantschel","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.09.011_bib0240","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.23922","article-title":"Waldenstr\u00f6m macroglobulinemia: 2015 update on diagnosis, risk stratification, and management","volume":"90","author":"Gertz","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.phrs.2016.09.011_bib0245","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.09.011_bib0250","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1038\/bcj.2015.28","article-title":"Waldenstrom macroglobulinemia: prognosis and management","volume":"5","author":"Oza","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.phrs.2016.09.011_bib0255","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2015-01-553974","article-title":"How I treat Waldenstr\u00f6m macroglobulinemia","volume":"126","author":"Treon","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.09.011_bib0260","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1634\/theoncologist.2012-0279","article-title":"The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience","volume":"18","author":"Zafar","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.phrs.2016.09.011_bib0265","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2016.09.011_bib0270","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring: 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2016.09.011_bib0275","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.phrs.2016.09.011_bib0280","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chembiol.2012.12.006","article-title":"Developing irreversible inhibitors of the protein kinase cysteinome","volume":"20","author":"Liu","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.phrs.2016.09.011_bib0285","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1021\/jm101396q","article-title":"Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors","volume":"54","author":"Leproult","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2016.09.011_bib0290","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2016.09.011_bib0295","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1073\/pnas.72.8.3073","article-title":"Acetylation of prostaglandin synthase by aspirin","volume":"72","author":"Roth","year":"1975","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.09.011_bib0300","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1734-1140(10)70308-X","article-title":"Vane's discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology","volume":"62","author":"Botting","year":"2010","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.phrs.2016.09.011_bib0305","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/11596310-000000000-00000","article-title":"Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects","volume":"25","author":"Schapira","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2016.09.011_bib0310","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/bi00646a018","article-title":"The structure of the covalent adduct formed by the interaction of 3-dimethylamino-1-propyne and the flavine of mitochondrial amine oxidase","volume":"15","author":"Maycock","year":"1976","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2016.09.011_bib0315","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40272-013-0012-x","article-title":"Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics","volume":"15","author":"Ward","year":"2013","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.phrs.2016.09.011_bib0320","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1021\/jm901443h","article-title":"Through the gatekeeper door: exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2016.09.011_bib0325","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.phrs.2016.09.011_bib0330","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/cb500129t","article-title":"Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery?","volume":"9","author":"Zhao","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2016.09.011_bib0335","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1039\/C2MD20180A","article-title":"Approaches to discover non-ATP site inhibitors","volume":"4","author":"Gavrin","year":"2013","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.phrs.2016.09.011_bib0340","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.2174\/138161212800672813","article-title":"New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors","volume":"18","author":"Lamba","year":"2012","journal-title":"Curr. Pharm. Des."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816309227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816309227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,15]],"date-time":"2018-07-15T01:40:13Z","timestamp":1531618813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661816309227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":68,"alternative-id":["S1043661816309227"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2016.09.011","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2016.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}